NCT01969838 · ADVERSE EVENTS

Adverse events

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis · Source last updated 2023-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Serious and other Adverse events were recorded that occurred from initiation of investigational product (IP) until 30 days after the last administration of IP regardless of cause or relationship. Serious events are monitored up to 12 weeks and all-cause mortality was assessed for up to 5 years.
Other-event reporting threshold: 5%

The safety population did not include 2 patients (one on MMB and one on RUX) who were not dosed, hence affecting the total number of patients at risk.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Momelotinib (MMB) Participants received momelotinib plus placebo to match ruxolitinib. Momelotinib tablets were administered orally once daily at a starting dose of 200 mg. Additional available strengths included 100 mg and 150 mg. Placebo to match ruxolitinib tablets were administered orally twice daily.	49 / 214	197 / 214	8 / 214
Ruxolitinib (RUX) Participants received ruxolitinib plus placebo to match momelotinib. Ruxolitinib tablets were administered orally twice daily. The dose ranged from 5 to 20 mg BID and was dependent on platelet count, creatinine clearance, and transaminase levels. Placebo to match momelotinib tablets were administered orally once daily.	39 / 216	206 / 216	6 / 216
MMB to MMB After completion of the 24-week double-blind treatment phase, participants had the option to receive MMB in an open-label treatment phase for up to an additional 216 weeks. Participants randomized to the MMB group at study entry continued MMB in the open-label treatment phase at their current dose. Available MMB strengths were 100 mg, 150 mg and 200 mg.	79 / 171	153 / 171	44 / 171
RUX to MMB After completion of the 24-week double-blind treatment phase, participants had the option to receive MMB in an open-label treatment phase for up to an additional 216 weeks. Participants randomized to the RUX group who wished to remain in the study initiated MMB in the open-label treatment phase at the dose matching their equivalent MMB placebo dose. Available MMB strengths were 100 mg, 150 mg and 200 mg.	79 / 197	188 / 197	54 / 197

Group identifiers: EG000: Momelotinib (MMB) · EG001: Ruxolitinib (RUX) · EG002: MMB to MMB · EG003: RUX to MMB

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
4
num At Risk
214
group Id
EG001
num Affected
8
num At Risk
216
group Id
EG002
num Affected
7
num At Risk
171
group Id
EG003
num Affected
4
num At Risk
197
term
Anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
2
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Febrile neutropenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
1
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Haemolytic anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
1
num At Risk
197
term
Leukopenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
1
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Microangiopathic haemolytic anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
1
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
1
num At Risk
197
term
Neutropenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
2
num At Risk
197
term
Splenic haematoma
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
1
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
3
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Splenic infarction
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
1
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Splenic thrombosis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
3
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
4
num At Risk
197
term
Thrombocytopenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
1
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Thrombocytosis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
2
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
1
num At Risk
171
group Id
EG003
num Affected
1
num At Risk
197
term
Acute myocardial infarction

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
21
num At Risk
214
group Id
EG001
num Affected
24
num At Risk
216
group Id
EG002
num Affected
13
num At Risk
171
group Id
EG003
num Affected
26
num At Risk
197
term
Abdominal pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
10
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
5
num At Risk
171
group Id
EG003
num Affected
11
num At Risk
197
term
Alanine aminotransferase increased
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
30
num At Risk
214
group Id
EG001
num Affected
79
num At Risk
216
group Id
EG002
num Affected
38
num At Risk
171
group Id
EG003
num Affected
29
num At Risk
197
term
Anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Musculoskeletal and connective tissue disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
15
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
10
num At Risk
171
group Id
EG003
num Affected
13
num At Risk
197
term
Arthralgia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
12
num At Risk
214
group Id
EG001
num Affected
16
num At Risk
216
group Id
EG002
num Affected
13
num At Risk
171
group Id
EG003
num Affected
12
num At Risk
197
term
Asthenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Musculoskeletal and connective tissue disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
10
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
10
num At Risk
171
group Id
EG003
num Affected
19
num At Risk
197
term
Back pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
9
num At Risk
214
group Id
EG001
num Affected
2
num At Risk
216
group Id
EG002
num Affected
10
num At Risk
171
group Id
EG003
num Affected
10
num At Risk
197
term
Blood creatinine increased
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Musculoskeletal and connective tissue disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
3
num At Risk
214
group Id
EG001
num Affected
15
num At Risk
216
group Id
EG002
num Affected
4
num At Risk
171
group Id
EG003
num Affected
12
num At Risk
197
term
Bone pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
21
num At Risk
214
group Id
EG001
num Affected
15
num At Risk
216
group Id
EG002
num Affected
13
num At Risk
171
group Id
EG003
num Affected
18
num At Risk
197
term
Constipation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Injury, poisoning and procedural complications
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
16
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
9
num At Risk
171
group Id
EG003
num Affected
5
num At Risk
197
term
Contusion
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Respiratory, thoracic and mediastinal disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
18
num At Risk
214
group Id
EG001
num Affected
17
num At Risk
216
group Id
EG002
num Affected
23
num At Risk
171
group Id
EG003
num Affected
34
num At Risk
197
term
Cough
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
11
num At Risk
214
group Id
EG001
num Affected
13
num At Risk
216
group Id
EG002
num Affected
15
num At Risk
171
group Id
EG003
num Affected
15
num At Risk
197
term
Decreased appetite

Complete source fields

description

The safety population did not include 2 patients (one on MMB and one on RUX) who were not dosed, hence affecting the total number of patients at risk.

event Groups

deaths Num Affected
8
deaths Num At Risk
214
description
Participants received momelotinib plus placebo to match ruxolitinib. Momelotinib tablets were administered orally once daily at a starting dose of 200 mg. Additional available strengths included 100 mg and 150 mg. Placebo to match ruxolitinib tablets were administered orally twice daily.
id
EG000
other Num Affected
197
other Num At Risk
214
serious Num Affected
49
serious Num At Risk
214
title
Momelotinib (MMB)
deaths Num Affected
6
deaths Num At Risk
216
description
Participants received ruxolitinib plus placebo to match momelotinib. Ruxolitinib tablets were administered orally twice daily. The dose ranged from 5 to 20 mg BID and was dependent on platelet count, creatinine clearance, and transaminase levels. Placebo to match momelotinib tablets were administered orally once daily.
id
EG001
other Num Affected
206
other Num At Risk
216
serious Num Affected
39
serious Num At Risk
216
title
Ruxolitinib (RUX)
deaths Num Affected
44
deaths Num At Risk
171
description
After completion of the 24-week double-blind treatment phase, participants had the option to receive MMB in an open-label treatment phase for up to an additional 216 weeks. Participants randomized to the MMB group at study entry continued MMB in the open-label treatment phase at their current dose. Available MMB strengths were 100 mg, 150 mg and 200 mg.
id
EG002
other Num Affected
153
other Num At Risk
171
serious Num Affected
79
serious Num At Risk
171
title
MMB to MMB
deaths Num Affected
54
deaths Num At Risk
197
description
After completion of the 24-week double-blind treatment phase, participants had the option to receive MMB in an open-label treatment phase for up to an additional 216 weeks. Participants randomized to the RUX group who wished to remain in the study initiated MMB in the open-label treatment phase at the dose matching their equivalent MMB placebo dose. Available MMB strengths were 100 mg, 150 mg and 200 mg.
id
EG003
other Num Affected
188
other Num At Risk
197
serious Num Affected
79
serious Num At Risk
197
title
RUX to MMB

frequency Threshold

other Events

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
21
num At Risk
214
group Id
EG001
num Affected
24
num At Risk
216
group Id
EG002
num Affected
13
num At Risk
171
group Id
EG003
num Affected
26
num At Risk
197
term
Abdominal pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
10
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
5
num At Risk
171
group Id
EG003
num Affected
11
num At Risk
197
term
Alanine aminotransferase increased
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
30
num At Risk
214
group Id
EG001
num Affected
79
num At Risk
216
group Id
EG002
num Affected
38
num At Risk
171
group Id
EG003
num Affected
29
num At Risk
197
term
Anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Musculoskeletal and connective tissue disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
15
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
10
num At Risk
171
group Id
EG003
num Affected
13
num At Risk
197
term
Arthralgia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
12
num At Risk
214
group Id
EG001
num Affected
16
num At Risk
216
group Id
EG002
num Affected
13
num At Risk
171
group Id
EG003
num Affected
12
num At Risk
197
term
Asthenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Musculoskeletal and connective tissue disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
10
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
10
num At Risk
171
group Id
EG003
num Affected
19
num At Risk
197
term
Back pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Investigations
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
9
num At Risk
214
group Id
EG001
num Affected
2
num At Risk
216
group Id
EG002
num Affected
10
num At Risk
171
group Id
EG003
num Affected
10
num At Risk
197
term
Blood creatinine increased
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Musculoskeletal and connective tissue disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
3
num At Risk
214
group Id
EG001
num Affected
15
num At Risk
216
group Id
EG002
num Affected
4
num At Risk
171
group Id
EG003
num Affected
12
num At Risk
197
term
Bone pain
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
21
num At Risk
214
group Id
EG001
num Affected
15
num At Risk
216
group Id
EG002
num Affected
13
num At Risk
171
group Id
EG003
num Affected
18
num At Risk
197
term
Constipation
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Injury, poisoning and procedural complications
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
16
num At Risk
214
group Id
EG001
num Affected
10
num At Risk
216
group Id
EG002
num Affected
9
num At Risk
171
group Id
EG003
num Affected
5
num At Risk
197
term
Contusion
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Respiratory, thoracic and mediastinal disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
18
num At Risk
214
group Id
EG001
num Affected
17
num At Risk
216
group Id
EG002
num Affected
23
num At Risk
171
group Id
EG003
num Affected
34
num At Risk
197
term
Cough
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Metabolism and nutrition disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
11
num At Risk
214
group Id
EG001
num Affected
13
num At Risk
216
group Id
EG002
num Affected
15
num At Risk
171
group Id
EG003
num Affected
15
num At Risk
197
term
Decreased appetite

serious Events

assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
4
num At Risk
214
group Id
EG001
num Affected
8
num At Risk
216
group Id
EG002
num Affected
7
num At Risk
171
group Id
EG003
num Affected
4
num At Risk
197
term
Anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
2
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Febrile neutropenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
1
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Haemolytic anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
1
num At Risk
197
term
Leukopenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
1
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Microangiopathic haemolytic anaemia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
1
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
1
num At Risk
197
term
Neutropenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
2
num At Risk
197
term
Splenic haematoma
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
1
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
3
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Splenic infarction
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
1
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Splenic thrombosis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
0
num At Risk
214
group Id
EG001
num Affected
3
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
4
num At Risk
197
term
Thrombocytopenia
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
1
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
0
num At Risk
171
group Id
EG003
num Affected
0
num At Risk
197
term
Thrombocytosis
assessment Type
NON_SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
source Vocabulary
MedDRA (22.0)
stats
group Id
EG000
num Affected
2
num At Risk
214
group Id
EG001
num Affected
0
num At Risk
216
group Id
EG002
num Affected
1
num At Risk
171
group Id
EG003
num Affected
1
num At Risk
197
term
Acute myocardial infarction

time Frame

Serious and other Adverse events were recorded that occurred from initiation of investigational product (IP) until 30 days after the last administration of IP regardless of cause or relationship. Serious events are monitored up to 12 weeks and all-cause mortality was assessed for up to 5 years.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice